Ghrelin Peptide Protects Brain Cell Growth in Stress-Induced Depression Model
Background
Chronic stress, often modeled by chronic unpredictable mild stress (CUMS) in animals, is a major contributor to major depressive disorder and is associated with impaired hippocampal neurogenesis (the birth of new neurons in the hippocampus, a brain region critical for mood and memory). While Ghrelin (a hunger-regulating peptide hormone) and its receptor GHSR are known to influence mood and stress responses, their specific role in protecting hippocampal neurogenesis against CUMS-induced damage was not fully understood. This study aimed to investigate the protective effects of Ghrelin/GHSR signaling on hippocampal neurogenesis in CUMS mice.
Results
CUMS significantly impaired hippocampal neurogenesis and induced depressive-like behaviors in mice. However, Ghrelin treatment, particularly at the higher dose, notably reversed these detrimental effects. > Specifically, Ghrelin at 0.5 mg/kg increased the number of BrdU+ cells (a marker for cell proliferation) in the dentate gyrus by 43% compared to the CUMS vehicle group (p<0.001). Furthermore, Ghrelin treatment led to a 2.5-fold increase in DCX+ cells (immature neurons) and a 1.8-fold increase in NeuN+/BrdU+ cells (mature new neurons) in the hippocampus (p<0.01 for both), indicating enhanced neuronal survival and differentiation. This neurogenic effect was accompanied by a 35% reduction in stress-induced depressive-like behaviors in the forced swim test (p<0.05), demonstrating a functional improvement.
Why It Matters
This study provides compelling evidence that Ghrelin/GHSR signaling plays a crucial role in protecting hippocampal neurogenesis from chronic stress-induced damage, leading to improved mood-related behaviors. This suggests that Ghrelin or its agonists could represent a novel therapeutic strategy for stress-related psychiatric disorders, such as major depressive disorder and post-traumatic stress disorder (PTSD), by directly addressing neurobiological deficits. These findings highlight a promising pathway for developing new treatments that promote brain plasticity and resilience against chronic stress. Future research should focus on optimizing Ghrelin analogs and delivery methods, moving towards preclinical toxicology and eventually human clinical trials.